One-stop-shop for artificial intelligence applications launched.
CHICAGO - Finding and purchasing AI imaging applications just got a bit easier.
IBM Watson Health Imaging announced the launch of its Imaging AI Marketplace at this year’s annual meeting of the Radiological Society of North America in Chicago. The single-source solution marketplace is designed to help streamline the process of locating, buying, deploying, and managing the ever-growing options for AI Imaging applications. The one-stop-shop experience simplifies a process that can be complex and resource-draining.
As a carefully-controlled database of AI applications, the IBM Imaging AI Marketplace only includes solutions that have been cleared by the U.S. Food & Drug Administration, as well as AI solutions developed by Watson Health. This vetted catalog offers solutions for a wide range of specialties and modalities to meet customer needs.
In addition to this extensive collection of applications, the Imaging AI Marketplace also helps customers deploy AI imaging applications into their existing clinical workflow, potentially minimizing disruptions to physician productivity, and maximizing patient care.
Customers can access the Imaging AI Marketplace via IBM Watson Health’s iConnect™ Enterprise Archive.
To date, IBM Watson Health Imaging has several vendor partners for its Imaging AI Marketplace. So far, the company has partnered with Circle Cardiovascular Imaging, DiA Imaging Analysis Ltd., MaxQAI, Quantib BV, VIDA LungPrint.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.